3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
83
Neoplasm Metastasis
9
Prostatic Neoplasms, Castration-Resistant
5
Neoplasms
3
Metastatic Castration-Resistant Prostate Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Urogenital Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Primary Myelofibrosis
2
Pancreatic Neoplasms
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Metastatic Castration-resistant Prostate Cancer (mCRPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Colorectal Neoplasms
2
Castration-resistant Prostate Cancer
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Thrombocytosis
1
Prostatic Diseases
1
Prostate Cancer Metastatic Disease
1
Prostate Adenocarcinoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Ovarian Neoplasms
1
Interventions
enzalutamide
5
abiraterone
2
Radiotherapy
2
Metastasectomy
2
Abiraterone Acetate
2
testosterone enanthate
1
radium Ra 223 dichloride
1
pembrolizumab
1
disitamab vedotin
1
dactolisib
1
VT-464
1
Radium-223
1
Radiosurgery
1
Prednisone
1
NVP-BKM120
1
Ketoconazole
1
Injections
1
Hydrocortisone
1
Flutamide
1
Cyclophosphamide
1
Crizotinib
1
Control Groups
1
Carboplatin
1
Calcitriol
1
Blood Specimen Collection
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Castration-resistant Prostate Cancer
×
abiraterone
×
Genitourinary
×
Clear all
NCT04839055
2021-04-09
CoA-CRPC
Jiangnan University
Phase 1/2
Unknown
50 enrolled
NCT02429193
2020-01-13
BARRIER-P
University Health Network, Toronto
Phase 2
Completed
16 enrolled